calidibio.com - CLDI Operating profit EBITDA
The development of Calidi Biotherapeutics (CLDI) relies on viral cell delivery and FDA approval. Demand for cancer immunotherapy remains stable, ensuring the business's macro-resilience. The company strictly adheres to bio-waste ethics and laboratory energy conservation. The absolute operating profit reflects smoothed cash flow dynamics, where the current status equals 0.00, masking potential capital expenditures.
Calidi Biotherapeutics, Inc. (CLDI) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Equity Ratio Calidi Biotherapeutics|CLDI - Long-Term Debt to Capital|Short-Term Debt to Capital Calidi Biotherapeutics Inc.|CLDI - Company Debts|Debt to Book Capitalization Ratio Calidi Biotherapeutics|CLDI - Company Long-Term Debts|Short-Term Debt Volume Calidi Biotherapeutics|Immediate Liquidity Ratio calidibio.com
- earnings and market ratios statistics:
CLDI - Net Profit|Company Profit Forecast Calidi Biotherapeutics|CLDI - Price to Earnings Ratio|Future Price to Earnings Multiple Calidi Biotherapeutics Inc.|CLDI - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Calidi Biotherapeutics|CLDI - Operating profit EBITDA|Net earnings per share for the last four quarters Calidi Biotherapeutics|CLDI - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months calidibio.com|CLDI - Net earnings per share growth this year|Projected earnings per share increase next year Calidi Biotherapeutics
Analysis of all company metrics:Calidi Biotherapeutics (CLDI)
The absence of current sales and high development costs for oncology platforms make Calidi Biotherapeutics (CLDI) dependent on external financing. This EBITDA result captures the company's real-time cash flows from core operations, eliminating accounting assumptions and allowing investors to assess the business's current financial resilience to external shocks without quarterly delays.
Who Calidi Biotherapeutics competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit EBITDA PSNL|Operating profit before deduction of amortization erasca.com ERAS|Operating profit EBITDA DCTH (Delcath Systems)|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|AURA - Profit before payment of interest, taxes and amortization|CADL: Profit before payment of interest, taxes and amortization|ARAY: Operating profit EBITDA|SLS - Operating income before deduction of amortization|ACTU (Actuate Therapeutics) - Operating profit EBITDA|Operating profit before amortization CTOR (Citius Oncology Inc.)|Operating profit EBITDA HURA|Operating income before deduction of amortization Protara Tx|Fate Therapeutics, Inc. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization WHWK|TScan - Operating profit EBITDA|CSBR: Profit before payment of interest, taxes and amortization|XBIT: Operating profit EBITDA|CVM - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization OS Therapies Incorporated|Profit before interest, taxes and amortization radiopharmtheranostics.com RADX|Operating profit before deduction of amortization ARTV (Artiva Biotherapeutics, Inc.)|Company profit before taxes, interest and amortization ANL|Operating profit EBITDA VERU (Veru Pharma)|Income before deduction of interest, taxes and amortization TPST|Xilio - Operating profit EBITDA|Profit before interest, taxes and amortization Renovaro Inc.|muraloncology.com (MURA) - Profit before payment of interest, taxes and amortization|Kairos Pharma - Income before deduction of interest, taxes and amortization|OKUR (OnKure Therapeutics, Inc.) - Operating profit EBITDA|Operating profit EBITDA CytoMed|Profit before payment of interest, taxes and amortization Curis, Inc. (CRIS)|APLM: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA THAR (Tharimmune)|Advanced Biomed Inc. (ADVB) - Profit before interest, taxes and amortization|GNPX: Operating profit before deduction of amortization|SBFM - Operating profit EBITDA|XBIO (xeneticbio.com) - Operating profit before deduction of amortization|SLRX: Company profit before taxes, interest and amortization|PPBT (Purple Biotech Ltd.) - Operating profit EBITDA|AON (AONC) - Operating income before deduction of amortization|Operating profit EBITDA BGNE|Operating profit before deduction of amortization Checkpoint Therapeutics Inc CKPT|Profit before payment of interest, taxes and amortization Elevation Oncology ELEV|Operating income before deduction of amortization iCAD Inc. (ICAD)|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|viracta.com (VIRX) - Profit before payment of interest, taxes and amortization|MOR (MorphoSys Corporation) - Profit before payment of interest, taxes and amortization|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit before amortization AAPGV (ascentage.com)
